MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaccinex, Inc. - Common Stock (NQ:VCNX)

1.410 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vaccinex, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
This first-in-class differentiated approach will be highlighted during a Featured Research Session entitled Alzheimer's therapy: mechanisms beyond amyloid 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports 2025 Annual Financial Results
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discovery 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Pepinemab appears to enhance clinical activity of immune checkpoint inhibitors via induction of mature tertiary lymphoid structures in tumors of patients with HPV-negative head and neck cancer. 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain
Company describes new biomarker and cognitive treatment effects that support continued development of pepinemab in Mild Cognitive Impairment and Mild Dementia due to Alzheimer’s disease 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
In addition to cognitive benefit, pepinemab is believed to preserve vascular integrity in brain, a key consideration to avoid toxicity in Alzheimer’s disease 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s disease 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Pepinemab is believed to block astrocyte reactivity, a key pathology driving Alzheimer’s progression 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex, Inc. Announces Reverse Stock Split
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with... 
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex Announces Pricing of $9.6 Million Public Offering
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration
From Vaccinex, Inc.
Via GlobeNewswire
News headline image
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
From Vaccinex, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story